loading
Precedente Chiudi:
$48.94
Aprire:
$49.08
Volume 24 ore:
11.83M
Relative Volume:
0.82
Capitalizzazione di mercato:
$98.56B
Reddito:
$47.64B
Utile/perdita netta:
$5.42B
Rapporto P/E:
18.14
EPS:
2.67
Flusso di cassa netto:
$13.09B
1 W Prestazione:
+2.26%
1M Prestazione:
+3.75%
6M Prestazione:
-18.84%
1 anno Prestazione:
+6.98%
Intervallo 1D:
Value
$47.29
$49.24
Intervallo di 1 settimana:
Value
$46.57
$49.27
Portata 52W:
Value
$44.00
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Nome
Bristol Myers Squibb Co
Name
Telefono
(609) 252-4621
Name
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Dipendente
34,100
Name
Cinguettio
@BMSNEWS
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BMY's Discussions on Twitter

Confronta BMY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
48.43 99.60B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
812.69 723.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.30 407.97B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.28 337.08B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.70 227.39B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.70 314.28B 43.59B 15.04B 10.74B 3.3766

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-04-22 Iniziato Piper Sandler Overweight
2024-12-16 Aggiornamento Jefferies Hold → Buy
2024-12-10 Ripresa BofA Securities Neutral
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-13 Aggiornamento Daiwa Securities Neutral → Outperform
2024-11-12 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-25 Downgrade Citigroup Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-07-29 Downgrade Barclays Overweight → Equal Weight
2024-03-11 Downgrade Societe Generale Buy → Hold
2024-02-06 Downgrade Redburn Atlantic Buy → Neutral
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-02 Downgrade Daiwa Securities Outperform → Neutral
2023-10-27 Downgrade BMO Capital Markets Outperform → Market Perform
2023-10-27 Aggiornamento HSBC Securities Reduce → Hold
2023-10-27 Downgrade William Blair Outperform → Mkt Perform
2023-10-20 Ripresa UBS Neutral
2023-07-14 Iniziato HSBC Securities Reduce
2023-07-10 Iniziato SVB Securities Market Perform
2023-06-28 Iniziato Daiwa Securities Outperform
2023-03-06 Iniziato Jefferies Hold
2023-01-17 Iniziato Cantor Fitzgerald Overweight
2022-11-18 Iniziato Credit Suisse Neutral
2022-10-10 Downgrade Guggenheim Buy → Neutral
2022-09-14 Downgrade Berenberg Buy → Hold
2022-06-03 Downgrade Raymond James Outperform → Mkt Perform
2022-04-06 Ripresa Morgan Stanley Underweight
2021-12-17 Iniziato Goldman Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-11-01 Downgrade Argus Buy → Hold
2021-07-27 Ripresa Truist Buy
2021-04-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-04-13 Aggiornamento Truist Hold → Buy
2020-11-16 Aggiornamento Societe Generale Hold → Buy
2020-11-10 Ripresa Bernstein Mkt Perform
2020-11-06 Downgrade Gabelli & Co Buy → Hold
2020-10-19 Aggiornamento Guggenheim Neutral → Buy
2020-09-29 Iniziato Berenberg Buy
2020-07-28 Iniziato Raymond James Outperform
2020-04-02 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-01-06 Ripresa Citigroup Buy
2019-12-13 Aggiornamento Argus Hold → Buy
2019-11-22 Ripresa Morgan Stanley Equal-Weight
2019-10-17 Ripresa BofA/Merrill Buy
2019-08-14 Aggiornamento Atlantic Equities Neutral → Overweight
2019-05-28 Iniziato Goldman Buy
2019-05-20 Downgrade Argus Buy → Hold
2019-05-03 Aggiornamento Barclays Equal Weight → Overweight
2019-05-03 Ripresa JP Morgan Overweight
2019-01-15 Aggiornamento Societe Generale Sell → Buy
2018-10-22 Downgrade Citigroup Buy → Neutral
Mostra tutto

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

pulisher
Jul 25, 2025

Ex-BMS General Counsel Joins Bausch Health Board - Law360

Jul 25, 2025
pulisher
Jul 25, 2025

Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects - GlobeNewswire Inc.

Jul 25, 2025
pulisher
Jul 25, 2025

Bristol Myers’ Top Doctor Exits in Midst of Search for New Hit Drug - Bloomberg

Jul 25, 2025
pulisher
Jul 25, 2025

Bristol Myers Squibb Taps AstraZeneca's Star Executive Who Led 150+ Clinical Studies as New CMO - Stock Titan

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Bristol Myers Squibb Company Equity Right stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock? - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' - Benzinga

Jul 24, 2025
pulisher
Jul 24, 2025

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab - Pharma Voice

Jul 24, 2025
pulisher
Jul 23, 2025

Jim Cramer on Bristol-Myers: “Never Seen it This Cheap” - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Dr Reddy's kicks off India big pharma earnings with narrow profit miss - Reuters

Jul 23, 2025
pulisher
Jul 23, 2025

Citi Keeps Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

Bristol-Myers Squibb’s Promising CELMoD Pipeline and Revenue Growth Potential: Analyst Buy Rating - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Bristol Myers Squibb Company Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions - PharmTech

Jul 22, 2025
pulisher
Jul 22, 2025

Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - simplywall.st

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Bristol Myers Squibb Company stock priceFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Jim Cramer Reflected on These 17 Stocks - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com

Jul 18, 2025
pulisher
Jul 18, 2025

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.

Jul 18, 2025
pulisher
Jul 18, 2025

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

Jul 18, 2025
pulisher
Jul 18, 2025

13 Cheap Stocks Under $50 to Buy Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Major drugmakers offer big discount on blood thinner Eliquis - Fox Business

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

BMS/Pfizer Offer Direct-to-Consumer Option for Eliquis - Managed Healthcare Executive

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025

Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$50.37
price up icon 0.48%
drug_manufacturers_general PFE
$24.79
price down icon 2.21%
$116.20
price up icon 2.65%
$306.58
price down icon 0.64%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
drug_manufacturers_general NVO
$71.70
price up icon 1.37%
Capitalizzazione:     |  Volume (24 ore):